Steven Projan
Keine laufenden Positionen mehr
Vermögen: 8 732 $ am 31.03.2024
Profil
Steven J.
Projan served as the Director at Idenix Pharmaceuticals LLC from 2009 to 2010.
He was also the Vice President & Head-Biological at Wyeth Pharmaceuticals LLC from 2008 to 2010, and the Vice President-Global & Head-Infectious Disease at Novartis Corp.
from 2008 to 2010.
Additionally, he held the position of Senior Vice President-Research & Development at Medimmune, Inc. from 2010 to 2018.
Dr. Projan's former jobs also include serving as an Independent Director at Evaxion Biotech A from 2020 to 2023.
He holds a doctorate degree from The Trustees of Columbia University in The City of New York and an undergraduate degree from Massachusetts Institute of Technology.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
EVAXION BIOTECH A/S
0,14% | 31.03.2023 | 27 288 ( 0,14% ) | 8 732 $ | 31.03.2024 |
Ehemalige bekannte Positionen von Steven Projan
| Unternehmen | Position | Ende |
|---|---|---|
| EVAXION BIOTECH A/S | Director/Board Member | 01.05.2023 |
| Medimmune, Inc. | Chief Tech/Sci/R&D Officer | 01.04.2018 |
| IDENIX PHARMACEUTICALS INC | Director/Board Member | 11.08.2010 |
Wyeth Pharmaceuticals LLC
 Wyeth Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Wyeth Pharmaceuticals LLC develops pharmaceutical, biotechnology and vaccine technologies. The company was registered on May 5, 2003 and is headquartered in Collegeville, PA. | Corporate Officer/Principal | 01.01.2010 |
Novartis Corp.
 Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Corporate Officer/Principal | 01.01.2010 |
Ausbildung von Steven Projan
| The Trustees of Columbia University in The City of New York | Doctorate Degree |
| Massachusetts Institute of Technology | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| EVAXION BIOTECH A/S | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Idenix Pharmaceuticals LLC
 Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA. | Health Technology |
Wyeth Pharmaceuticals LLC
Wyeth Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Wyeth Pharmaceuticals LLC develops pharmaceutical, biotechnology and vaccine technologies. The company was registered on May 5, 2003 and is headquartered in Collegeville, PA. | Health Technology |
Novartis Corp.
Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Health Technology |
| Medimmune, Inc. | Health Technology |
